Sirpiglenastat

Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response[1][2].

Product Specifications

CAS Number

[2079939-05-0]

Product Name Alternative

DRP-104

UNSPSC

12352005

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sirpiglenastat.html

Purity

99.13

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@@H](NC(C)=O)CC1=CNC2=CC=CC=C12)=O)=O

Molecular Formula

C22H27N5O5

Molecular Weight

441.48

References & Citations

[1]Yumi Yokoyama, et al. DRP-104, a novel broad acting glutamine antagonist, induces distinctive immune modulation mechanisms and synergistic efficacy in combination with immune checkpoint blockade. J Immunother Cancer. 2019 Nov 6;7 (Suppl 1) :282.|[2]Yumi Yokoyama, et al. DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo. Cancer Res 2021;81 (13_Suppl) :Abstract nr 1563.